SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Applied Therapeutics, Inc. due to allegations of securities law violations related to misleading statements and undisclosed adverse facts concerning the company's clinical trials and regulatory submissions [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $50,000 in Applied Therapeutics to discuss their legal options [1]. - A federal securities class action has been filed against Applied Therapeutics, with a deadline of February 18, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that the company and its executives made false statements and failed to disclose significant issues regarding the Phase III INSPIRE trial, which misled investors [4]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA regarding the New Drug Application for govorestat, Applied Therapeutics' stock price fell by$1.64 per share, or 16.06%, closing at $8.57 on November 27, 2024 [5]. - After the FDA issued a Warning Letter indicating that the company was aware of significant issues with the govorestat NDA, the stock price dropped by$0.31 per share, or 18.34%, closing at $1.38 on December 4, 2024 [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].